Clinical Trials Browser

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT00416767 2016-05-30

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Phase 2 Completed

20 enrolled

Endocrine

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00096083 2013-10-23

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Phase 2 Completed

56 enrolled

DermatologicEndocrineGastrointestinal

Adenocarcinoma Of Esophagus, Uveal Melanoma, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Melanoma, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Rectal Neoplasms, Somatostatinoma, Stomach Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Phase 2 Completed

84 enrolled

Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00027638 2013-06-18

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2 Completed

EndocrineThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00075439 2013-06-04

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Phase 2 Completed

90 enrolled

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00017199 2013-01-31

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2 Completed

Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma

Clinical Trials

OCCLURANDOM

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

PALBONET

Capecitabine and Temozolomide for Neuroendocrine Cancers

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors